文献速递神经免疫

多发性硬化疾病修饰治疗与COVID-19严重程度的关联

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-10-05

该国际多中心队列研究分析了28个国家12个数据源中多发性硬化合并COVID-19的患者,发现利妥昔单抗与住院、ICU入住和人工通气风险增加相关,奥瑞珠单抗与住院和ICU入住风险增加相关,但未观察到与死亡的关联。

要点

  • 利妥昔单抗与COVID-19住院、ICU入住和人工通气风险增加相关。
  • 奥瑞珠单抗与COVID-19住院和ICU入住风险增加相关。
  • 高龄、进展型MS表型和较高残疾与更差COVID-19结局相关。

核心结论

  • 利妥昔单抗与COVID-19住院、ICU入住和需要人工通气风险增加一致相关。
  • 奥瑞珠单抗与COVID-19住院和ICU入住风险增加相关。
  • 未观察到疾病修饰治疗与死亡的关联。

研究设计与样本

  • 国际多中心队列研究,汇总28个国家12个数据源的数据。
  • 采用多水平混合效应逻辑回归,调整年龄、性别、MS表型和EDSS评分。

主要发现

  • 疑似加确诊和仅确诊COVID-19患者中,住院比例分别为20.9%和26.9%,ICU入住为5.4%和7.2%,人工通气为4.1%和5.4%,死亡为3.2%和3.9%。
  • 与富马酸二甲酯相比,奥瑞珠单抗和利妥昔单抗与住院相关(aOR 1.56, 95%CI 1.01-2.41; aOR 2.43, 95%CI 1.48-4.02),与ICU入住相关(aOR 2.30, 95%CI 0.98-5.39; aOR 3.93, 95%CI 1.56-9.89),仅利妥昔单抗与人工通气相关(aOR 4.00, 95%CI 1.54-10.39)。
  • 与汇总的其他DMT相比,奥瑞珠单抗和利妥昔单抗与住院相关(aOR 1.75, 95%CI 1.29-2.38; aOR 2.76, 95%CI 1.87-4.07)和ICU入住相关(aOR 2.55, 95%CI 1.49-4.36; aOR 4.32, 95%CI 2.27-8.23),仅利妥昔单抗与人工通气相关(aOR 6.15, 95%CI 3.09-12.27)。
  • 与那他珠单抗相比,奥瑞珠单抗和利妥昔单抗与住院相关(aOR 1.86, 95%CI 1.13-3.07; aOR 2.88, 95%CI 1.68-4.92)和ICU入住相关(aOR 2.13, 95%CI 0.85-5.35; aOR 3.23, 95%CI 1.17-8.91),仅利妥昔单抗与人工通气相关(aOR 5.52, 95%CI 1.71-17.84)。
  • 限制于确诊病例时关联持续存在,未观察到DMT与死亡的关联。

临床怎么用

  • 使用利妥昔单抗或奥瑞珠单抗的MS患者可能面临更严重COVID-19风险,临床决策需权衡感染风险。

局限性

  • 研究为横断面设计,无法确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. METHODS: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. RESULTS: Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01-2.41; aOR 2.43, 95% CI 1.48-4.02) and ICU admission (aOR 2.30, 95% CI 0.98-5.39; aOR 3.93, 95% CI 1.56-9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29-2.38; aOR 2.76, 95% CI 1.87-4.07) and ICU admission (aOR 2.55, 95% CI 1.49-4.36; aOR 4.32, 95% CI 2.27-8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13-3.07; aOR 2.88, 95% CI 1.68-4.92) and ICU admission (aOR 2.13, 95% CI 0.85-5.35; aOR 3.23, 95% CI 1.17-8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71-17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. DISCUSSION: Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021. PMID: 34610987. doi:10.1212/WNL.0000000000012753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。